Xcout Intel
Amphista
Amphista Therapeutics is a Cambridge-based biopharmaceutical spin-out company redefining targeted protein degradation through its proprietary Targeted Glues technology. Headquartered in Great Abington, United Kingdom, the company goes beyond traditional CRBN-based degradation approaches.
Subscribe to see Amphista’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amphista at a glance
Amphista is a biotechnology company headquartered in United Kingdom. Xcout tracks 12 named people at Amphista, including Louise Modis (Chief Executive Officer).
Amphista leadership
- Louise ModisChief Executive Officer
- Ali ElsleyChief Financial Officer
- Martin PassChief Development Officer
- Patrick KellyChief Medical Officer
- Lisa H. ButlerSVP Clinical Operations
- John GoodallVP BD & Operations
6 more named people on record for Amphista, with roles, board committees and tenure — see the full roster →
Amphista competitors
A few of Amphista's closest competitors — see the full list of competitors and alternatives →
TRIMTECH Therapeutics is a biotechnology company headquartered in Cambridge, United Kingdom, focused on developing targeted protein degradation therapies like TRIMTAC and TRIMGLUE.
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
76Bio, Inc. is a biotechnology company founded in 2020 and based in Boston, United States. The company develops therapeutics for patients with life-threatening diseases by pioneering targeted protein degraders.
Quarry Thera builds next-generation induced proximity therapeutics by engineering oral small molecules for applications in immunology and oncology. The company develops precision chemistry platforms, including Surface Interaction Domain Targeting Glues and Tissue-Targeting Glues, utilizing molecular glues and heterobifunctionals to unlock novel pharmacology.
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
Get Amphista's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Amphista? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amphista in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access